DINNER SHORT COURSES*

15 November, 19:00-21:30

Dinner Provided

(SC1) New Technologies for Improving Drug Safety Screening - Detailed Agenda

This course will bring together experts who will discuss the use of new technologies and platforms for early, predictive drug safety screening. Focus will be on the use and validation of simple and complex cell systems, including induced pluripotent stem cells (iPSC), 3D cells and organ-on-a-chip systems for assessing cardiotoxicity and hepatotoxicity. The course will be conducted in an informal, interactive setting and will provide attendees time for networking and discussions.

Instructors: Christopher Goldring, Ph.D., Senior Lecturer, Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool

James J. Hickman, Ph.D., Founding Director, NanoScience Technology Center and Professor, Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering, University of Central Florida

Ard C.H. Teisman, Ph.D., Scientific Director, Global Safety Pharmacology, Discovery Sciences, Janssen Research & Development

(SC2) Humanized Mouse Models: Technology and Applications in Preclinical Assessment of Cancer Immunotherapy - Detailed Agenda

Humanized mouse models have been developed as immunologically relevant models for preclinical profiling of cancer immunotherapies. The course will describe different types of humanized mouse models, their immune characterization, and specific examples of their application in the field of Cancer Immunotherapy. The course will highlight advantages and pitfalls of currently available humanized mouse models and will give an overview of the next generation improved humanized models designed to better address specific immunological questions.

Instructors: Laurie Kenney, Ph.D, Postdoctoral Fellow, University of Massachusetts Medical School

Sara Colombetti, Ph.D., Group Leader, Immunopharmacodynamics and Pharmacokinetics, Pharmacology Department, Roche Innovation Center Zürich

16 November, 18:30-21:00

Dinner Provided

(SC3) Evaluating Immuno-Oncology Treatment with PK/PD Modelling - Detailed Agenda

Complex mechanisms of action of cancer immune-therapies require advanced PK/PD modelling for interpretation of results. This short course will cover the basics of PK/PD modeling in immune-oncology as well as share some case studies of successful models. It will help attendees to learn about dose selection, estimation of therapeutic window, trial designs, and therapeutic regimens, based on preclinical PK/PD modeling.

Instructor: Tao You, Ph.D., PK/PD Modelling Lab Head, Boehringer Ingelheim

(SC4) Patient-Derived Organoid for Drug Development and Screening - Detailed Agenda

Recently, a number of technological advances in stem cell biology have prompted the development of better in vitro models for biological systems. Using organoid technology, stem cell-derived human epithelial ‘mini-organs’ (organoids) can be generated from tissues of patients with various diseases including cancer and cystic fibrosis. These culture models stably maintain the genotype/phenotype of the patient’s diseased tissue, thereby representing an in vitro platform for preclinical drug discovery and validation and a tool for precision medicine.

Instructor: Sylvia F. Boj, Ph.D., Scientific Director, Hubrecht Organoid Technology (HUB)

(SC5) The Role of Drug Transporters in Drug Research and Development - Detailed Agenda

This short course will focus on basic aspects of active drug transporters and their impact in drug research and development. The workshop will cover conceptual aspects of experimental design, including principal set-up, pitfalls and data interpretation. The relevance of drug transport processes for key ADME and safety properties will be discussed and exemplified with different case studies. The audience will learn where and how drug transport properties can be optimized throughout lead-optimization to improve drug absorption and distribution, organ targeting and drug safety.

Instructors: Bruno Stieger, Ph.D., Group Leader, Department of Clinical Pharmacology and Toxicology, University Hospital, Zurich

Christoph Funk, Ph.D., Head, Mechanistic ADME, Roche Innovation Center Basel, F. Hoffmann-La Roche

* Separate registration required